
CTEK - More than meets the eye

Redeye updates its estimates following CTEK's Q4 report, which was largely impacted by General Motors generating one-time sales and write-downs simultaneously. CTEK generated solid underlying organic growth despite tough comps, but profitability was slightly below our estimates due to long-term investments putting a short-term dent in the margins. We are optimistic about 2025 for CTEK and consider the upcoming CMD a potential catalyst in increasing the stock market's general understanding of the company's ongoing business.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[CTEK - More than meets the eye](#)